Physicians Briefing reports a Swedish study that shows a lower risk of mortality (I vote that is a better outcome) with oral type 2 medications than with insulin. Good to see the study considered hypos. Given that diabetes is underestimated as a cause of death, it is good to see research looking at the big picture of all-cause mortality.
WEDNESDAY, Feb. 8, 2017 (HealthDay News) — For patients with type 2 diabetes, novel oral glucose lowering drugs (GLDs) are associated with reduced risks of all-cause mortality, cardiovascular disease (CVD), and hypoglycemia, compared with insulin use, according to a study published online Jan. 24 in Diabetes, Obesity and Metabolism.
Still – YDMV. The best course of treatment is the one the patient and physician agree meets the individual needs.
I think this “all-cause” approach should be taken when considering access to care beyond medications. One size doesn’t fit all. Disrupting access to diabetes tool from strips, to the appropriate pump should be considered on a similar basis.